Multisystem inflammatory syndrome in children: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Multisystem inflammatory syndrome in children | |||
| image = [[File:Novel_Coronavirus_SARS-CoV-2.jpg|alt=Image of SARS-CoV-2 virus]] | |||
| caption = The virus SARS-CoV-2, which is associated with MIS-C | |||
| field = [[Pediatrics]] | |||
| symptoms = [[Fever]], [[abdominal pain]], [[vomiting]], [[diarrhea]], [[rash]], [[conjunctivitis]], [[hypotension]] | |||
| complications = [[Cardiac dysfunction]], [[shock]], [[coronary artery aneurysm]] | |||
| onset = Typically 2-6 weeks after [[SARS-CoV-2]] infection | |||
| duration = Varies | |||
| causes = [[SARS-CoV-2]] infection | |||
| risks = [[COVID-19]] exposure | |||
| diagnosis = Clinical evaluation, laboratory tests, imaging | |||
| differential = [[Kawasaki disease]], [[toxic shock syndrome]], [[sepsis]] | |||
| prevention = [[COVID-19 vaccination]], [[infection control]] measures | |||
| treatment = [[Intravenous immunoglobulin]], [[corticosteroids]], [[supportive care]] | |||
| prognosis = Generally good with treatment, but can be severe | |||
| frequency = Rare | |||
| deaths = Rare, but can occur | |||
}} | |||
[[File:Verkalkte aneurysmatische Coronarien.jpg|Multisystem inflammatory syndrome in children|thumb|left]] | |||
'''Multisystem Inflammatory Syndrome in Children''' (MIS-C), also known as '''Paediatric Inflammatory Multisystem Syndrome''' (PIMS), is a serious health condition that primarily affects children and is believed to be linked to [[COVID-19]]. | '''Multisystem Inflammatory Syndrome in Children''' (MIS-C), also known as '''Paediatric Inflammatory Multisystem Syndrome''' (PIMS), is a serious health condition that primarily affects children and is believed to be linked to [[COVID-19]]. | ||
== Introduction == | |||
== | |||
MIS-C is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. The syndrome was first reported in April 2020, during the global [[COVID-19 pandemic]]. It is thought to be a post-infectious syndrome, meaning it arises following a primary infection, in this case, [[SARS-CoV-2]], the virus that causes COVID-19. | MIS-C is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. The syndrome was first reported in April 2020, during the global [[COVID-19 pandemic]]. It is thought to be a post-infectious syndrome, meaning it arises following a primary infection, in this case, [[SARS-CoV-2]], the virus that causes COVID-19. | ||
== Symptoms == | == Symptoms == | ||
Symptoms of MIS-C can vary, but they often include fever, abdominal pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, and feeling extra tired. These symptoms are similar to those of other inflammatory conditions, such as [[Kawasaki disease]] and [[toxic shock syndrome]]. | Symptoms of MIS-C can vary, but they often include fever, abdominal pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, and feeling extra tired. These symptoms are similar to those of other inflammatory conditions, such as [[Kawasaki disease]] and [[toxic shock syndrome]]. | ||
== Diagnosis == | == Diagnosis == | ||
Diagnosis of MIS-C involves blood tests, chest x-ray, heart ultrasound ([[echocardiogram]]), and abdominal ultrasound. The [[Centers for Disease Control and Prevention]] (CDC) has provided a case definition for MIS-C that includes a fever, laboratory evidence of inflammation, severe illness requiring hospitalization, multisystem organ involvement, and evidence of COVID-19. | Diagnosis of MIS-C involves blood tests, chest x-ray, heart ultrasound ([[echocardiogram]]), and abdominal ultrasound. The [[Centers for Disease Control and Prevention]] (CDC) has provided a case definition for MIS-C that includes a fever, laboratory evidence of inflammation, severe illness requiring hospitalization, multisystem organ involvement, and evidence of COVID-19. | ||
== Treatment == | == Treatment == | ||
Treatment for MIS-C typically involves supportive care, as well as specific treatments to address inflammation. This can include [[corticosteroids]], intravenous [[immunoglobulin]] (IVIG), and other medications that reduce inflammation. | Treatment for MIS-C typically involves supportive care, as well as specific treatments to address inflammation. This can include [[corticosteroids]], intravenous [[immunoglobulin]] (IVIG), and other medications that reduce inflammation. | ||
== Prognosis == | == Prognosis == | ||
The prognosis for MIS-C is generally good, with most children recovering with appropriate medical care. However, in severe cases, MIS-C can lead to long-term health problems or even be life-threatening. | The prognosis for MIS-C is generally good, with most children recovering with appropriate medical care. However, in severe cases, MIS-C can lead to long-term health problems or even be life-threatening. | ||
== See also == | == See also == | ||
* [[COVID-19 pandemic]] | * [[COVID-19 pandemic]] | ||
* [[Kawasaki disease]] | * [[Kawasaki disease]] | ||
* [[Toxic shock syndrome]] | * [[Toxic shock syndrome]] | ||
{{stub}} | {{stub}} | ||
[[Category:Syndromes]] | [[Category:Syndromes]] | ||
| Line 32: | Line 40: | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Inflammatory diseases]] | [[Category:Inflammatory diseases]] | ||
Latest revision as of 05:24, 9 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Multisystem inflammatory syndrome in children | |
|---|---|
| |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, hypotension |
| Complications | Cardiac dysfunction, shock, coronary artery aneurysm |
| Onset | Typically 2-6 weeks after SARS-CoV-2 infection |
| Duration | Varies |
| Types | N/A |
| Causes | SARS-CoV-2 infection |
| Risks | COVID-19 exposure |
| Diagnosis | Clinical evaluation, laboratory tests, imaging |
| Differential diagnosis | Kawasaki disease, toxic shock syndrome, sepsis |
| Prevention | COVID-19 vaccination, infection control measures |
| Treatment | Intravenous immunoglobulin, corticosteroids, supportive care |
| Medication | N/A |
| Prognosis | Generally good with treatment, but can be severe |
| Frequency | Rare |
| Deaths | Rare, but can occur |
Multisystem Inflammatory Syndrome in Children (MIS-C), also known as Paediatric Inflammatory Multisystem Syndrome (PIMS), is a serious health condition that primarily affects children and is believed to be linked to COVID-19.
Introduction[edit]
MIS-C is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. The syndrome was first reported in April 2020, during the global COVID-19 pandemic. It is thought to be a post-infectious syndrome, meaning it arises following a primary infection, in this case, SARS-CoV-2, the virus that causes COVID-19.
Symptoms[edit]
Symptoms of MIS-C can vary, but they often include fever, abdominal pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, and feeling extra tired. These symptoms are similar to those of other inflammatory conditions, such as Kawasaki disease and toxic shock syndrome.
Diagnosis[edit]
Diagnosis of MIS-C involves blood tests, chest x-ray, heart ultrasound (echocardiogram), and abdominal ultrasound. The Centers for Disease Control and Prevention (CDC) has provided a case definition for MIS-C that includes a fever, laboratory evidence of inflammation, severe illness requiring hospitalization, multisystem organ involvement, and evidence of COVID-19.
Treatment[edit]
Treatment for MIS-C typically involves supportive care, as well as specific treatments to address inflammation. This can include corticosteroids, intravenous immunoglobulin (IVIG), and other medications that reduce inflammation.
Prognosis[edit]
The prognosis for MIS-C is generally good, with most children recovering with appropriate medical care. However, in severe cases, MIS-C can lead to long-term health problems or even be life-threatening.
